Cargando…
P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430638/ http://dx.doi.org/10.1097/01.HS9.0000972520.32337.3f |
| _version_ | 1785091014417973248 |
|---|---|
| author | Boissel, Nicolas Chevallier, Patrice Curran, Kevin Schiller, Gary Liu, Hongtau Larson, Richard Deangelo, Daniel J. Mear, Jean-Baptiste Grupp, Stephan Baruchel, André Konopleva, Marina Lacroce, Alexandra Roudet, Caroline Korngold, Ana Newhall, Katie Laille, Eric Lee, Daniel Frattini, Mark Jain, Nitin |
| author_facet | Boissel, Nicolas Chevallier, Patrice Curran, Kevin Schiller, Gary Liu, Hongtau Larson, Richard Deangelo, Daniel J. Mear, Jean-Baptiste Grupp, Stephan Baruchel, André Konopleva, Marina Lacroce, Alexandra Roudet, Caroline Korngold, Ana Newhall, Katie Laille, Eric Lee, Daniel Frattini, Mark Jain, Nitin |
| author_sort | Boissel, Nicolas |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430638 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104306382023-08-17 P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) Boissel, Nicolas Chevallier, Patrice Curran, Kevin Schiller, Gary Liu, Hongtau Larson, Richard Deangelo, Daniel J. Mear, Jean-Baptiste Grupp, Stephan Baruchel, André Konopleva, Marina Lacroce, Alexandra Roudet, Caroline Korngold, Ana Newhall, Katie Laille, Eric Lee, Daniel Frattini, Mark Jain, Nitin Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430638/ http://dx.doi.org/10.1097/01.HS9.0000972520.32337.3f Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Boissel, Nicolas Chevallier, Patrice Curran, Kevin Schiller, Gary Liu, Hongtau Larson, Richard Deangelo, Daniel J. Mear, Jean-Baptiste Grupp, Stephan Baruchel, André Konopleva, Marina Lacroce, Alexandra Roudet, Caroline Korngold, Ana Newhall, Katie Laille, Eric Lee, Daniel Frattini, Mark Jain, Nitin P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) |
| title | P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) |
| title_full | P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) |
| title_fullStr | P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) |
| title_full_unstemmed | P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) |
| title_short | P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) |
| title_sort | p1408: updated results of the phase i balli-01 trial of ucart22, an anti-cd22 allogeneic car-t cell product, in patients with relapsed or refractory (r/r) cd22+ b-cell acute lymphoblastic leukemia (b-all) |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430638/ http://dx.doi.org/10.1097/01.HS9.0000972520.32337.3f |
| work_keys_str_mv | AT boisselnicolas p1408updatedresultsofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedorrefractoryrrcd22bcellacutelymphoblasticleukemiaball AT chevallierpatrice p1408updatedresultsofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedorrefractoryrrcd22bcellacutelymphoblasticleukemiaball AT currankevin p1408updatedresultsofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedorrefractoryrrcd22bcellacutelymphoblasticleukemiaball AT schillergary p1408updatedresultsofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedorrefractoryrrcd22bcellacutelymphoblasticleukemiaball AT liuhongtau p1408updatedresultsofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedorrefractoryrrcd22bcellacutelymphoblasticleukemiaball AT larsonrichard p1408updatedresultsofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedorrefractoryrrcd22bcellacutelymphoblasticleukemiaball AT deangelodanielj p1408updatedresultsofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedorrefractoryrrcd22bcellacutelymphoblasticleukemiaball AT mearjeanbaptiste p1408updatedresultsofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedorrefractoryrrcd22bcellacutelymphoblasticleukemiaball AT gruppstephan p1408updatedresultsofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedorrefractoryrrcd22bcellacutelymphoblasticleukemiaball AT baruchelandre p1408updatedresultsofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedorrefractoryrrcd22bcellacutelymphoblasticleukemiaball AT konoplevamarina p1408updatedresultsofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedorrefractoryrrcd22bcellacutelymphoblasticleukemiaball AT lacrocealexandra p1408updatedresultsofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedorrefractoryrrcd22bcellacutelymphoblasticleukemiaball AT roudetcaroline p1408updatedresultsofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedorrefractoryrrcd22bcellacutelymphoblasticleukemiaball AT korngoldana p1408updatedresultsofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedorrefractoryrrcd22bcellacutelymphoblasticleukemiaball AT newhallkatie p1408updatedresultsofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedorrefractoryrrcd22bcellacutelymphoblasticleukemiaball AT lailleeric p1408updatedresultsofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedorrefractoryrrcd22bcellacutelymphoblasticleukemiaball AT leedaniel p1408updatedresultsofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedorrefractoryrrcd22bcellacutelymphoblasticleukemiaball AT frattinimark p1408updatedresultsofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedorrefractoryrrcd22bcellacutelymphoblasticleukemiaball AT jainnitin p1408updatedresultsofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedorrefractoryrrcd22bcellacutelymphoblasticleukemiaball |